17,261 trials
Breast Cancer
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to World Health Organization (WHO) Handbook for Reporting Results of…
Major Cutaneous Abscess · Cellulitis · Erysipelas
Primary: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) — 91 participants
Vitiligo
Primary: Number of Participants With a Decrease in Vitiligo Area Scoring Index (VASI) Score — 0; 0 Participants
Ulcerative Colitis
Primary: Number of Participants Experiencing a Treatment Emergent Adverse Event — 3; 9; 10 participants
Fallopian Tube Cancer · Malignant Tumor of Peritoneum · Recurrent Ovarian Epithelial Cancer
Primary: Maximum Tolerated Dose of VEGF Trap (Phase I) — 6 mg/kg
Renal Cancer · Von Hippel Lindau
Primary: Overall Response Rate. — 3; 0; 75; 0 percentage of participants
Ovarian Cancer
Primary: Response Rate — 0; 1; 8; 6 Participants
Rheumatoid Arthritis
Primary: Number of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response (20% Improvement) — 18; 8 Participants — p=0.0352
Rheumatoid Arthritis
Primary: ACR20 at Week 12 — 29; 34; 33 participants
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome (MDS)
Primary: Progression Free Survival (PFS) at 7 Months — 65 percentage of participants
Meningitis, Meningococcal, Serogroup B
Primary: Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ) — 6; 5; 6; 3…
Meningococcal Disease
Primary: Percentage of Subjects With Bactericidal Titers ≥1:4 Against Meningococcal Strains One Month After Second and Third Vaccination of rMenB Vaccine With and Without OMV-NZ…
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer
Primary: PSA Response — 0 participants
Healthy Volunteers
Primary: The Effects of Storage-related RBC Changes on Acetylcholine-stimulated (NO-mediated) Forearm Blood Flow. — 19.02; 18.42; 17.61; 22.89 mL / 100 mL / min
Diabetes Mellitus, Type 2 · Atherosclerosis · Prediabetic State
Primary: Number of Participants With Adverse Events, Serious Adverse Events and Death — 80; 77; 14; 25 Number of participants